We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Guidant shareholders overwhelmingly approved the proposed $25.4 billion sale of the Indiana-based devicemaker to Johnson & Johnson (J&J) in a special April 27 meeting.
Devicemaker Medtronic has identified an additional 396 LIFEPAK 500 automated external defibrillators (AEDs) for inclusion in its voluntary recall of several models of the device, bringing the number of affected machines to 2,320.
St. Jude Medical reported a $206 million jump in its implantable cardioverter-defibrillator (ICD) sales for the first quarter, up 72 percent over last year’s first-quarter earnings.
A “Dear Colleague” letter signed by 39 House members pledged their support for a 2.79 percent inflationary increase for the FDA’s Center for Devices and Radiological Health (CDRH) in President Bush’s 2006 budget.
AdvaMed updated its “Code of Ethics” April 18 to include answers to more specific questions concerning gifts and other types of financial support that members may provide to healthcare professionals.
Medtronic recently announced the launch of its Restore Rechargeable Neurostimulation System for people suffering from chronic pain. FDA approved the device earlier this month.
One week prior to announcing its impressive first-quarter earnings, Boston Scientific said it would exercise its option to acquire three device companies: Rubicon, TriVascular and CryoVascular.
Johnson & Johnson (J&J) exceeded analyst expectations by posting another quarter of double-digit growth amounting to more than 17.4 percent, much of it attributed to the company’s $4.8 billion in sales of medical devices and diagnostics worldwide.
A Medtronic spokesperson dismissed as “without merit” a recent class action lawsuit launched against the company on behalf of users of several types of its defibrillators manufactured between April 2001 and December 2003.